OncoMatch/Clinical Trials/NCT07108998
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
Is NCT07108998 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Epcoritamab for cll/sll.
Treatment: Epcoritamab — This is a phase 2 study of Epcoritamab as a consolidation therapy for 2nd generation BTKi +/- Obinutuzumab in CLL/SLL patients or patients with variants of this.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 expression (presence required)
Absence of CD20 expression on CLL cells at pre-treatment [excluded]
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
ECOG performance status ≤2 (or Karnofsky ≥60%)
Prior therapy
Must have received: BTK inhibitor (acalabrutinib, zanubrutinib) — first line
received a 2nd generation BTKi (acalabrutinib or zanubrutinib) +/- obinutuzumab for a minimum of 12 months as first line therapy
Cannot have received: CD3×CD20 bispecific antibody
Received any prior treatment ever with a CD3×CD20 bispecific antibody
Lab requirements
Blood counts
Absolute neutrophil count ≥1,000/mcL (unless due to CLL); Hemoglobin ≥8 g/dl (unless due to CLL); Platelets ≥50,000/µL (unless due to CLL)
Kidney function
GFR ≥ 30 mL/min/1.73m² (CKD-EPI)
Liver function
Total bilirubin ≤ 1.5 x ULN (except Gilbert's syndrome); AST/ALT ≤3 × ULN
Cardiac function
No significant cardiovascular disease (uncontrolled arrhythmias, CHF, MI within 180 days, NYHA Class 3/4, LVEF ≤ 40%)
Absolute neutrophil count ≥1,000/mcL, unless if neutropenia is due to underlying CLL bone marrow disease. Hemoglobin ≥8 g/dl unless if related to underlying CLL Platelets ≥50,000/ µL unless if related to underlying CLL Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (excepting Gilbert's syndrome...). AST(SGOT)/ALT(SGPT) ≤3 × institutional ULN Glomerular filtration rate (GFR) Calculated GFR using CKD-EPI formula ≥ 30... Patient has significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 180 days prior to the first dose of study drug, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification or left ventricular ejection fraction ≤ 40%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Cincinnati · Cincinnati, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify